FIELD: medicine, pharmaceutics.
SUBSTANCE: present invention refers to medicine, namely to pharmacology and describes a histidine-free pharmaceutical composition containing high-purity factor VIII; arginine and saccharose, a surfactant for the prevention or at least the inhibition of a surface adsorption of factor VIII; 0.5 to 10 mM calcium chloride for the specific stabilisation of factor VIII, and sodium citrate or maleic acid as a pH buffer.
EFFECT: invention provides the protective function for preserve high-yield factor VIII over the whole cycle of pharmaceutical processing, long storage and end recovery and administration into the patient.
18 cl, 16 tbl, 8 ex
| Title | Year | Author | Number |
|---|---|---|---|
| NOVEL STABILISER FOR PHARMACEUTICAL PROTEINS | 2011 |
|
RU2571496C2 |
| NOVEL STABILIZER FOR PHARMACEUTICAL PROTEINS | 2011 |
|
RU2707090C2 |
| NEW ALBUMIN-FREE COMPOSITIONS OF FACTOR VIII | 2000 |
|
RU2244556C2 |
| COMPOSITION CONTAINING PREPARATION OF CLOTTING FACTOR VIII, METHOD OF ITS PREPARING AND USE OF SURFACE-ACTIVE SUBSTANCE AS STABILIZING AGENT | 1993 |
|
RU2136294C1 |
| COMPOSITION OF FACTOR VIII | 2015 |
|
RU2689338C2 |
| STABLE, ALBUMIN-FREE, LYOPHILIZED COMPOSITION OF RECOMBINANT FACTOR VIII | 1997 |
|
RU2201252C2 |
| STABLE AQUEOUS COMPOSITIONS OF PROTEIN MIA/CD-RAP | 2011 |
|
RU2588658C2 |
| STABLE AQUEOUS PROTEIN COMPOSITIONS OF MIA/CD-RAP | 2011 |
|
RU2739078C2 |
| DRY COMPOSITION OF TRANSGLUTAMINE | 2009 |
|
RU2616847C2 |
| STABLE ISOTONIC LYOPHILIZED PROTEIN COMPOSITION | 1996 |
|
RU2229288C2 |
